EHA 2022 | Prognostic value of CXCR4 mutations & thrombocytopenia in patients with WM treated with ibrutinib
Jorge Castillo, MD, Dana-Farber Cancer Institute, Boston, MA, comments on the results of a study investigating factors associated with progression-free survival (PFS) in patients with Waldenström’s macroglobulinemia (WM) treated with ibrutinib monotherapy. In agreement with previous studies, the study identified CXRC4 mutations as a factor indicative of a worse PFS. Interestingly, the study also showed that thrombocytopenia prior to the initiation of ibrutinib therapy was also associated with a poorer prognosis. In addition, the study did not find a predictive value for the International Prognostic Scoring System for WM (IPSSWM) in this cohort, suggesting that a larger sample size and a longer follow-up are required to validate this marker in patients with WM treated with ibrutinib. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Consulting fees and/or research funds from Abbvie, AstraZeneca, BeiGene, Cellectar, Janssen, Pharmacyclics, Roche, TG Therapeutics.
